- In July 2024, Rgenta Therapeutics, a biotechnology company at the forefront of creating a novel class of oral small molecules aimed at RNA and RNA regulation for oncology and neurological disorders, received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for RGT-61159. This compound is being developed as a potential treatment for adenoid cystic carcinoma (ACC), colorectal cancer (CRC), other solid tumors, and acute myeloid leukemia (AML)
Frequently Asked Questions
The market is segmented based on Segmentation By Stages (1st Degree, 2nd Degree, 3rd Degree, and Others), Treatment (Medication, Surgery, and Others), Route of Administration (Oral, Parenteral, Inhalational, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Adenoids Market size was valued at USD 572.45 USD Million in 2023.
The Global Adenoids Market is projected to grow at a CAGR of 7% during the forecast period of 2024 to 2031.
The major players operating in the market include Mylan, Teva Pharmaceutical Industries, Sanofi, Pfizer, Novartis, Bayer, Merck & Co., Abbott, AbbVie, Sun Pharmaceutical Industries, Aurobindo Pharma, Lupin, Hikma Pharmaceuticals, Amneal Pharmaceuticals, B. Braun SE.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
